CANCER IMMUNOTHERAPY BY DISRUPTING PD 1/PD L1 SIGNALING

摘要

The disclosure provides a method for immunotherapy of a cancer patient comprises administering to the patient an Ab that inhibits signaling from the PD 1/PD L1 signaling pathway or a combination of such Ab and an anti CTLA 4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD L1 on the cell surface exceeds a predetermined threshold level and administering an anti PD 1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface expressed PD L1 antigen in a FFPE tissue sample and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti PD L1 Abs.